Press Releases

- Effective immediately, agreement enables hundreds of people in Italy to access this important medicine - - Recent pricing and reimbursement agreements have enabled broad access to ORKAMBI for thousands of eligible patients in multiple European countries; negotiations continue in a number of other

BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in

- Presentation of data from a Phase 3 study of ORKAMBI in children ages 6-11 with two copies of the F508del mutation demonstrated improvements in lung function and sweat chloride; study also published online in The Lancet Respiratory Medicine today - - ECFS data presentations demonstrate that

BOSTON --(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today elected Alan M. Garber , M.D., Ph.D. as an independent member of its board of directors. Dr. Garber is Provost of Harvard University , the Mallinckrodt Professor of Health Care Policy at Harvard

-Agreement provides access to ORKAMBI for people who have two copies of the F508del mutation and expands access to KALYDECO for all eligible patients- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement with the Health Service

- New Program Helps CF Families Pursue Higher Education - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will be awarded $5,000 for the

BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in the

- Precision medicine decision based on in vitro data and supported by more than five years of real-world clinical data that demonstrate KALYDECO's strong safety and efficacy profile for eligible patients - - Vertex working with FDA to obtain rapid approval for more than 600 additional people who

Third Annual CF "Circle of Care" Grants Connect CF Community Members Around the World to Share Their Ideas and Inspiration BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an

-First-quarter 2017 cystic fibrosis product revenues of $481 million ; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million -

BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

  - Study in people who have two copies of the F508del mutation demonstrated a mean absolute improvement in ppFEV 1 of 4.0 percentage points compared to placebo (p

-Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals

BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the "Investors"

-2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO- -Fourth-quarter 2016 total CF product revenues of $454 million ; $277 million for ORKAMBI and $177 million for KALYDECO- -Company reiterates 2017 financial

-Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated

-Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI

BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 12:30 p.m. ET ( 9:30 a.m. PT ).

LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI ® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory Health Insurances (GKV-SV).

- Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) compared to placebo through 24 weeks of treatment - - ORKAMBI was well tolerated with safety data that were similar to data from previous Phase 3 open-label safety study -